Prana Biotechnology Limited (PRAN) Reaches $2.22 After 6.00% Up Move; Cincinnati Financial (CINF) Covered By 1 Bullish Analysts Last Week

May 23, 2018 - By Linda Rogers

Cincinnati Financial Corporation (NASDAQ:CINF) Logo

Among 4 analysts covering Cincinnati Fincl (NASDAQ:CINF), 1 have Buy rating, 1 Sell and 2 Hold. Therefore 25% are positive. Cincinnati Fincl had 17 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Buy” rating by M Partners given on Thursday, June 9. The rating was maintained by RBC Capital Markets on Thursday, July 30 with “Sector Perform”. Keefe Bruyette & Woods maintained the shares of CINF in report on Monday, September 18 with “Hold” rating. The stock of Cincinnati Financial Corporation (NASDAQ:CINF) has “Sector Perform” rating given on Thursday, April 28 by RBC Capital Markets. RBC Capital Markets maintained Cincinnati Financial Corporation (NASDAQ:CINF) on Thursday, October 29 with “Sector Perform” rating. The stock has “Buy” rating by M Partners on Friday, July 15. RBC Capital Markets maintained Cincinnati Financial Corporation (NASDAQ:CINF) on Thursday, February 8 with “Hold” rating. M Partners initiated Cincinnati Financial Corporation (NASDAQ:CINF) rating on Wednesday, September 2. M Partners has “Buy” rating and $60.0 target. The stock of Cincinnati Financial Corporation (NASDAQ:CINF) has “Hold” rating given on Monday, October 9 by RBC Capital Markets. On Thursday, December 21 the stock rating was maintained by Keefe Bruyette & Woods with “Hold”. See Cincinnati Financial Corporation (NASDAQ:CINF) latest ratings:

08/02/2018 Broker: RBC Capital Markets Rating: Hold New Target: $76.0 Maintain
21/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $75.0 Maintain
04/12/2017 Broker: Keefe Bruyette & Woods Rating: Hold New Target: $73.0 Maintain

The stock of Prana Biotechnology Limited (NASDAQ:PRAN) is a huge mover today! The stock increased 13.85% or $0.27 during the last trading session, reaching $2.22. About 78,957 shares traded or 277.33% up from the average. Prana Biotechnology Limited (NASDAQ:PRAN) has declined 10.28% since May 23, 2017 and is downtrending. It has underperformed by 21.83% the S&P500.The move comes after 7 months positive chart setup for the $19.28 million company. It was reported on May, 23 by Barchart.com. We have $2.35 PT which if reached, will make NASDAQ:PRAN worth $1.16M more.

Since February 9, 2018, it had 3 buys, and 0 selling transactions for $91,865 activity. On Friday, February 9 the insider Skidmore Douglas S bought $45,923. Debbink Dirk J bought $19,983 worth of Cincinnati Financial Corporation (NASDAQ:CINF) on Friday, May 11. Osborn David P bought $25,959 worth of stock or 370 shares.

Cincinnati Financial Corporation engages in the property casualty insurance business in the United States. The company has market cap of $11.58 billion. It operates through five divisions: Commercial Lines Insurance, Personal Lines Insurance, Excess and Surplus Lines Insurance, Life Insurance, and Investments. It has a 11.27 P/E ratio. The Commercial Lines Insurance segment provides coverage for commercial casualty, commercial property, commercial auto, and workersÂ’ compensation.

The stock decreased 0.80% or $0.57 during the last trading session, reaching $70.88. About 210,741 shares traded. Cincinnati Financial Corporation (NASDAQ:CINF) has risen 2.74% since May 23, 2017 and is uptrending. It has underperformed by 8.81% the S&P500.

More notable recent Cincinnati Financial Corporation (NASDAQ:CINF) news were published by: Seekingalpha.com which released: “Cincinnati Financial (CINF) Investor Presentation – Slideshow” on May 07, 2018, also Bizjournals.com with their article: “Greater Cincinnati company joins 2018 Fortune 500 list” published on May 21, 2018, Seekingalpha.com published: “Cincinnati Financial’s (CINF) CEO Steven Justus Johnston on Q1 2018 Results – Earnings Call Transcript” on April 26, 2018. More interesting news about Cincinnati Financial Corporation (NASDAQ:CINF) were released by: Seekingalpha.com and their article: “Cincinnati Financial’s Q1 2018: Time To Invest In This Dividend King?” published on May 05, 2018 as well as Seekingalpha.com‘s news article titled: “Retirement Strategy: I Am Done Being Wrong About This Market” with publication date: May 16, 2018.

Investors sentiment increased to 1.17 in Q4 2017. Its up 0.27, from 0.9 in 2017Q3. It increased, as 26 investors sold Cincinnati Financial Corporation shares while 137 reduced holdings. 43 funds opened positions while 148 raised stakes. 100.84 million shares or 4.97% less from 106.11 million shares in 2017Q3 were reported. Moreover, State Board Of Administration Of Florida Retirement has 0.04% invested in Cincinnati Financial Corporation (NASDAQ:CINF) for 212,642 shares. Jpmorgan Chase & holds 0.04% or 2.70 million shares in its portfolio. Old Republic Int Corp, Illinois-based fund reported 579,700 shares. Fifth Third Financial Bank has invested 0.43% in Cincinnati Financial Corporation (NASDAQ:CINF). Trust Of Vermont owns 0.01% invested in Cincinnati Financial Corporation (NASDAQ:CINF) for 885 shares. Meiji Yasuda Asset Mgmt Company Ltd reported 14,867 shares. Toronto Dominion National Bank holds 0.01% of its portfolio in Cincinnati Financial Corporation (NASDAQ:CINF) for 64,696 shares. Caisse De Depot Et Placement Du Quebec holds 0% or 19,247 shares. Zurcher Kantonalbank (Zurich Cantonalbank) holds 0.02% or 30,613 shares. Automobile Association invested 0.01% of its portfolio in Cincinnati Financial Corporation (NASDAQ:CINF). Assetmark reported 62 shares stake. California State Teachers Retirement Sys has 0.04% invested in Cincinnati Financial Corporation (NASDAQ:CINF) for 272,096 shares. Sumitomo Mitsui Inc invested in 0.05% or 491,532 shares. The Georgia-based Voya Inv Ltd Liability Com has invested 0.01% in Cincinnati Financial Corporation (NASDAQ:CINF). Vantage Inv Advisors Ltd Liability Company holds 0.17% or 9,702 shares in its portfolio.

Among 2 analysts covering Prana Biotechnology Ltd (NASDAQ:PRAN), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Prana Biotechnology Ltd has $4.0 highest and $4 lowest target. $4’s average target is 80.18% above currents $2.22 stock price. Prana Biotechnology Ltd had 2 analyst reports since January 5, 2018 according to SRatingsIntel.

Prana Biotechnology Limited develops therapies for the treatment of Alzheimer's disease, Huntington disease, and other neurodegenerative disorders in Australia. The company has market cap of $19.28 million. The Company’s lead drug candidates include PBT2, which is in Phase IIb clinical trials for the treatment of AlzheimerÂ’s: and that is in Phase IIa clinical trials for the treatment of HuntingtonÂ’s diseases. It currently has negative earnings. The firm is also developing PBT434, which is in preclinical toxicology stage for the treatment for ParkinsonÂ’s disease and other movement disorders; and PBT 519 that is in preclinical toxicology stage for the treatment of brain cancer.

Cincinnati Financial Corporation (NASDAQ:CINF) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


>